share_log

HSBC Initiates Coverage On Actinium Pharma With Buy Rating, Announces Price Target of $11.6

HSBC Initiates Coverage On Actinium Pharma With Buy Rating, Announces Price Target of $11.6

匯豐銀行以買入評級開始對Actinium Pharma進行保險,宣佈目標股價爲11.6美元
Benzinga ·  2023/09/06 05:06

HSBC analyst Morten Herholdt initiates coverage on Actinium Pharma (AMEX:ATNM) with a Buy rating and announces Price Target of $11.6.

匯豐銀行分析師莫滕·赫霍爾特以買入評級開始對Actinium Pharma(AMEX: ATNM)進行報道,並宣佈目標股價爲11.6美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論